GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital.
Market Cap | 74.044 Billion | Shares Outstanding | 2.047 Billion | Avg 30-day Volume | 4.256 Million |
P/E Ratio | 11.4344 | Dividend Yield | 6.1474 | EPS | |
Price to Revenue | 1.9278 | Debt to Equity | 1.3048 | EBITDA | 11.109 Billion |
Price to Book Value | 4.5065 | Operating Margin | 22.8247 | Enterprise Value | 121.875 Billion |
Current Ratio | 0.914 | EPS Growth | 0.232 | Quick Ratio | 0.605 |
1 Yr BETA | 0.4048 | 52-week High/Low | 46.41 / 28.19 | Profit Margin | 18.7337 |
Operating Cash Flow Growth | 8.4766 | Altman Z-Score | 1.5084 | Free Cash Flow to Firm | 11.819 Billion |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
GSK PLC-SPON ADR GSK | 2023-02-08 20:15:04 UTC | 4.0729 | 0.4971 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 19:45:03 UTC | 4.0729 | 0.4971 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 19:15:04 UTC | 4.0729 | 0.4971 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 18:45:03 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 18:15:03 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 17:45:03 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 17:15:03 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 16:45:03 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 16:15:03 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 15:45:03 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 15:15:04 UTC | 4.1029 | 0.4671 | 3700000 |
GSK PLC-SPON ADR GSK | 2023-02-08 14:45:04 UTC | 4.1029 | 0.4671 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-08 14:15:04 UTC | 4.1029 | 0.4671 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-08 13:45:04 UTC | 4.1619 | 0.4081 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-08 13:15:03 UTC | 4.1619 | 0.4081 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-08 12:45:04 UTC | 4.1619 | 0.4081 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-07 22:15:03 UTC | 4.1619 | 0.4081 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-07 21:45:03 UTC | 4.1619 | 0.4081 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-07 21:15:03 UTC | 4.1619 | 0.4081 | 3300000 |
GSK PLC-SPON ADR GSK | 2023-02-07 20:45:04 UTC | 4.1619 | 0.4081 | 3300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund | GSK | -39758.0 shares, $-1170077.94 | 2022-09-30 | N-PORT |
Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund | GSK | -2968.0 shares, $-98448.56 | 2022-10-31 | N-PORT |
Congress Person | Party | Chamber | Filing | Filing Date | Transaction Date | Security Type | Owner | Transaction | Amount | |
---|---|---|---|---|---|---|---|---|---|---|
![]() |
representative Virginia Foxx | republican | House | Filing | 2022-08-16 | 2022-08-16 | JT | P | $1,001-$15,000 | |
![]() |
representative Virginia Foxx | republican | House | Filing | 2022-08-10 | 2022-08-10 | JT | P | $15,001-$50,000 | |
![]() |
representative Virginia Foxx | republican | House | Filing | 2022-08-09 | 2022-08-09 | JT | P | $1,001-$15,000 |